BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 32807021)

  • 1. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
    Riancho-Zarrabeitia L; Martínez-Taboada V; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Fernández-Nebro A; Calvo-Alén J; Menor-Almagro R; Tomero-Muriel E; Uriarte-Isacelaya E; Botenau A; Andres M; Freire-González M; Santos Soler G; Ruiz-Lucea E; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez-García J; Expósito L; Hernández-Beriaín JA; Horcada L; Aurrecoechea E; Pego-Reigosa JM
    Lupus; 2020 Oct; 29(12):1556-1565. PubMed ID: 32807021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
    Riancho-Zarrabeitia L; Martínez-Taboada VM; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Mena Vázquez N; Calvo-Alén J; Menor Almagro R; Tomero Muriel E; Uriarte Isacelaya E; Boteanu A; Andres M; Freire González M; Santos Soler G; Ruiz-Lucea ME; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez J; Expósito L; Hernández Beriaín JA; Horcada L; Aurrecoechea E; Pego Reigosa JM
    Clin Exp Rheumatol; 2021; 39(3):555-563. PubMed ID: 32828148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic lupus erythematosus and antiphospholipid syndrome - diagnostic and therapeutic problems].
    Zdrojewski Z
    Wiad Lek; 2018; 71(1 pt 1):40-46. PubMed ID: 29558350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome.
    Deák M; Bocskai M; Burcsár S; Dányi O; Fekete Z; Kovács L
    Lupus; 2014 Aug; 23(9):913-8. PubMed ID: 24729279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.
    Unlu O; Erkan D; Barbhaiya M; Andrade D; Nascimento I; Rosa R; Banzato A; Pengo V; Ugarte A; Gerosa M; Ji L; Efthymiou M; Branch DW; de Jesus GR; Tincani A; Belmont HM; Fortin PR; Petri M; Rodriguez E; Pons-Estel GJ; Knight JS; Atsumi T; Willis R; Zuily S; Tektonidou MG;
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):134-141. PubMed ID: 29669399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus.
    Ramirez GA; Canti V; Del Rosso S; Erra R; Moiola L; Magnoni M; Bozzolo EP; Manfredi AA; Rovere-Querini P
    Autoimmunity; 2020 Feb; 53(1):21-27. PubMed ID: 31782311
    [No Abstract]   [Full Text] [Related]  

  • 10. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus.
    Goldstein R; Moulds JM; Smith CD; Sengar DP
    J Rheumatol; 1996 Jul; 23(7):1173-9. PubMed ID: 8823688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
    Fischer K; Brzosko M; Walecka A; Ostanek L; Sawicki M
    Pol Arch Med Wewn; 2007; 117 Suppl():13-7. PubMed ID: 18778013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
    Front Immunol; 2019; 10():885. PubMed ID: 31134052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study.
    Ricard L; Laurent C; Papo M; Deriaz S; Catano J; Alamowitch S; Kayem G; Chasset F; De Moreuil C; Boffa JJ; Gerotziafas G; Elalamy I; Bornes M; Maillot F; Audemard-Verger A; Planche V; Ballot E; Fain O; Mekinian A
    Joint Bone Spine; 2022 Mar; 89(2):105297. PubMed ID: 34656751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiphospholipid syndrome in patients with systemic lupus erythematosus.
    Pons-Estel GJ; Andreoli L; Scanzi F; Cervera R; Tincani A
    J Autoimmun; 2017 Jan; 76():10-20. PubMed ID: 27776934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.
    Ramos-Casals M; Campoamor MT; Chamorro A; Salvador G; Segura S; Botero JC; Yagüe J; Cervera R; Ingelmo M; Font J
    Lupus; 2004; 13(10):777-83. PubMed ID: 15540510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catastrophic antiphospholipid syndromes in systemic lupus erythematosus.
    Stratta P; Canavese C; Ferrero S; Grill A; Salomone M; Schinco PC; Fusaro E; Montaruli B; Santi S; Piccoli G
    Ren Fail; 1999 Jan; 21(1):49-61. PubMed ID: 10048117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.